SNFGE SNFGE
 
Thématique :
- Foie
Originalité :
Réexamen
Solidité :
Intermédiaire
Doit faire évoluer notre pratique :
Dans certains cas
 
 
Nom du veilleur :
Professeur Christine SILVAIN
Coup de coeur :
 
 
Hepatology
  2016/03  
 
  2016 Mar;63(3):827-38  
  doi: 10.1002/hep.28368  
 
  Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study.  
 
  Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, Bellentani S; HCC-NAFLD Italian Study Group.  
  http://www.ncbi.nlm.nih.gov/pubmed/26599351  
 
 

Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome and may evolve into hepatocellular carcinoma (HCC). Only scanty clinical information is available on HCC in NAFLD. The aim of this multicenter observational prospective study was to assess the clinical features of patients with NAFLD-related HCC (NAFLD-HCC) and to compare them to those of hepatitis C virus (HCV)-related HCC. A total of 756 patients with either NAFLD (145) or HCV-related chronic liver disease (611) were enrolled in secondary care Italian centers. Survival was modeled according to clinical parameters, lead-time bias, and propensity analysis. Compared to HCV, HCC in NAFLD patients had a larger volume, showed more often an infiltrative pattern, and was detected outside specific surveillance. Cirrhosis was present in only about 50% of NAFLD-HCC patients, in contrast to the near totality of HCV-HCC. Regardless of tumor stage, survival was significantly shorter (P = 0.017) in patients with NAFLD-HCC, 25.5 months (95% confidence interval 21.9-29.1), than in those with HCV-HCC, 33.7 months (95% confidence interval 31.9-35.4). To eliminate possible confounders, a propensity score analysis was performed, which showed no more significant difference between the two groups. Additionally, analysis of patients within Milan criteria submitted to curative treatments did not show any difference in survival between NAFLD-HCC and HCV-HCC (respectively, 38.6 versus 41.0 months, P = nonsignificant)

CONCLUSIONS:

NAFLD-HCC is more often detected at a later tumor stage and could arise also in the absence of cirrhosis, but after patient matching, it has a similar survival rate compared to HCV infection; a future challenge will be to identify patients with NAFLD who require more stringent surveillance in order to offer the most timely and effective treatment. (Hepatology 2016;63:827-838).

 
Question posée
 
Quelles sont les caractéristiques des carcinomes hépatocellulaires (CHC) survenant sur NALFD comparés à ceux survenant sur infection VHC ?
 
Question posée
 
Etude prospectives de cas diagnostiqués dans des centres secondaires italiens.Les 145 CHC diagnostiqués associés à la NALFLD étaient de plus grande taille et plus infiltrants et sur cirrhose seulement de 50% des cas comparés à 100 % des cas en cas de CHC associés au VHC. La survie était plus courte pour les CHC sur NAFLD en relation avec un diagnostic trop tardif alors que la « potentiel » évolutif parait identique.
 
Commentaires

Diagnostic trop tardif mais qui surveiller ? cirrhose absente dans la moitié des cas ; comment surveiller ? A quelle fréquence ???

 
www.snfge.org